Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised phase II study of cetuximab plus gemcitabine versus gemcitabine followed by cetuximab in advanced NSCLC not suitable for platinum-based therapy
2004-002811-98Phase 2Completed
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Feb 2007
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab, gemcitabine in non-small cell lung cancer (NSCLC), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Started Feb 2007; status: completed.
02
Drugs
cetuximabgemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2004-002811-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002811-98.